Marico Ltd
MARICOMarico Ltd compounds quietly. Returns above 15% and growth without drama — priced like it.
Biggest watch item: the P/E sits at the 74th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (73 weeks in) while the P/E sits at the 74th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +27.1% year on year, and 97% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Marico Ltd trades at ₹802, in a confirmed uptrend and 73 weeks into that stage. That is +0.5% against its own 200-day average. It sits at 57% of a 52-week range of ₹712 to ₹871. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a confirmed uptrend — week 73 of stage 2, confirmed. At ₹802 it trades +0.5% versus its 200-day average and sits at 57% of its 52-week range (₹712–₹871).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +238% while the NIFTY 500 moved +273% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Marico Ltd trades at 55.2× P/E, at the pricey end of its own range (74th percentile). Its long-run median P/E is 51.8×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 55.2× is at the pricey end of its own range (74th percentile), against a long-run median of 51.8× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +8.0% against a +9.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +6.9%/yr price move, ~+9.6%/yr came from earnings growth and ~−2.7 pp from the multiple (compressing); over 10y, of the +10.6%/yr price move, ~+9.4%/yr came from earnings growth and ~+1.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Marico Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 47.0% and holding. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +25.7% | +11.7% | +11.1% | +8.5% |
| Profit | +9.3% | +11.1% | +8.6% | +9.6% |
| EPS | +8.0% | +10.5% | +8.4% | +9.4% |
| Share price | +9.2% | +11.0% | +6.9% | +10.6% |
4-Factor Sector Score
64.4/100 — rank 3 of 12 in FMCG - Personal Care · 82% evidence confidence
Marico Ltd scores 64.4 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 3. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 25.8 + 17.9 + 5.8 + 14.9 = 64.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Marico Ltd reported ₹3,957 Cr of revenue in the Jun 26 quarter, +22.9% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 8.5% a year. The last full year, FY26, came in at ₹13,611 Cr. The last four reported quarters add to ₹14,277 Cr.
FY26 revenue came in at ₹13,611 Cr (+25.7% on the year), capping 10 years at 8.5% compound. The latest quarter (Jun 26) printed ₹3,957 Cr, +22.9% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +25.3% growth against the decade's 8.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +25.1% over the last 4 quarters against +20.6%/yr over the last 8 — accelerating; TTM profit +15.0% vs +12.6%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Marico Ltd's operating margin is 21.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 21.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0%–21.0%.
Why the margin moved: operating margin went +0.4 pp year on year while gross margin went +0.3 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Marico Ltd earned ₹652 Cr of net profit in the Jun 26 quarter, +27.1% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹1,813 Cr. The 10-year compound rate is 9.6%. That is 16.5% of the quarter's revenue. The same quarter a year earlier earned ₹513 Cr.
Jun 26 profit was ₹652 Cr, +27.1% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹1,813 Cr (+9.3%), and the 10-year compound rate is 9.6%.
Why profit moved: revenue contributed +22.9% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +14.6% vs revenue +25.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 97% of Marico Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹2,084 Cr of operating cash against ₹1,813 Cr of profit. After ₹1,122 Cr of capital spending, ₹962 Cr was left as free cash.
FY26: operating cash of ₹2,084 Cr against reported profit of ₹1,813 Cr, leaving free cash of ₹962 Cr after ₹1,122 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 97% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 97%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 3.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Marico Ltd's cash conversion cycle runs 12 days in FY26, down from 17 days in FY21. Capital spending ran ₹1,943 Cr over the last 3 years. At FY26 sales of ₹13,611 Cr each day of that cycle holds about ₹37.3 Cr, so roughly ₹447 Cr sits inside the business at any moment.
FY26: debtors at 35 days, inventory at 85 days — roughly 2.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 12 days, tighter than FY21's 17.
The full loop: cash goes out to suppliers and production on day 0; stock waits 85 days to sell; customers pay about 35 days after that; and suppliers themselves are paid at 108 days — netting out to the 12-day cycle.
In money terms: at FY26 sales of ₹13,611 Cr, each day of the cycle holds about ₹37.3 Cr — so the 12-day loop keeps roughly ₹447 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,943 Cr over the last 3 fiscal years against ₹538 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹85.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Marico Ltd earns a ROCE of 47% in FY26. That is up from a trough of 29% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 13.3% net margin on 1.37× asset turns.
FY26 ROCE is 47%, recovered from a FY14 trough of 29% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.3% net margin × 1.37× asset turns × 2.36× balance-sheet leverage ≈ 43.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Marico Ltd carries ₹557 Cr of borrowings against ₹4,210 Cr of equity in FY26, a debt-to-equity of 0.13. Operating profit covers the interest bill 44×. Over 5 years borrowings went from ₹511 Cr to ₹557 Cr. Capital spending ran ₹1,943 Cr across the last 3 of those years.
FY26: borrowings of ₹557 Cr against equity of ₹4,210 Cr — a debt-to-equity of 0.13. Operating profit covers the interest bill 44×. Over 5 years borrowings went from ₹511 Cr to ₹557 Cr while capital spending ran ₹1,943 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 1.8 points of Marico Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 12.9% of the company. Foreign institutions moved −1.2 points over the same window, to 23.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +1.8 points over 8 quarters to 12.9%; Foreign institutions: −1.2 points over 8 quarters to 23.4%; Promoters: −0.4 points over 8 quarters to 58.9%.
Why the register moved: domestic institutions drove it (+1.8 points), absorbed on the other side by foreign institutions (−1.2 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Marico Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bajaj Consumer Care LtdBAJAJCON | 73.5/100Favorable setup100% evidence | ASLEEP | 32.3/35 Revenue 25.1% · PAT 77% · OPM change 9 pp 100% evidence | 16.9/25 ROCE 30% · OPM 24% 100% evidence | 10.3/20 P/E 30.5× · PEG 1.64 100% evidence | 14.0/20 RS sector 41.4% · RS bench 30.2% · 1Y 131.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 32.3 + 16.9 + 10.3 + 14 = 73.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Gillette India LtdGILLETTE | 67.2/100Favorable setup94% evidence | BASING | 23.9/35 Revenue 8% · PAT 18.4% · OPM change -1 pp 100% evidence | 18.6/25 ROCE 90.7% · OPM 29% 100% evidence | 14.5/20 P/E 35.6× · PEG 1.7 100% evidence | 10.2/20 RS sector -1.4% · RS bench -9.6% · 1Y -30.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 23.9 + 18.6 + 14.5 + 10.2 = 67.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Marico Ltdthis pageMARICO | 64.4/100Mixed-positive evidence82% evidence | ASLEEP | 25.8/35 Revenue 25.1% · PAT 15% · OPM change 1 pp 95% evidence | 17.9/25 ROCE 47% · OPM 21% 76% evidence | 5.8/20 P/E 55.2× · PEG — 50% evidence | 14.9/20 RS sector 13.6% · RS bench 4.3% · 1Y 9.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 25.8 + 17.9 + 5.8 + 14.9 = 64.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4Hindustan Unilever LtdHINDUNILVR | 61.6/100Mixed-positive evidence100% evidence | BASING | 24.7/35 Revenue 5.8% · PAT 38.3% · OPM change 0 pp 100% evidence | 14.0/25 ROCE 28.4% · OPM 23% 100% evidence | 16.9/20 P/E 41.1× · PEG 0.72 100% evidence | 6.0/20 RS sector -5% · RS bench -13.1% · 1Y -23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 14 + 16.9 + 6 = 61.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -5% and the one-year return is -23.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 5Dabur India LtdDABUR | 52.7/100Mixed-positive evidence94% evidence | BASING | 18.6/35 Revenue 7.4% · PAT 10.9% · OPM change 0 pp 100% evidence | 14.6/25 ROCE 20.3% · OPM 20% 100% evidence | 9.1/20 P/E 33.6× · PEG 5.04 100% evidence | 10.4/20 RS sector 0.3% · RS bench -18.4% · 1Y -31.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.6 + 9.1 + 10.4 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Procter & Gamble Hygiene and Health Care LtdPGHH | 49.5/100Mixed-negative evidence94% evidence | BASING | 13.4/35 Revenue -1.6% · PAT -4.7% · OPM change -9 pp 100% evidence | 18.3/25 ROCE 157% · OPM 19% 100% evidence | 14.0/20 P/E 30.9× · PEG 1.77 100% evidence | 3.8/20 RS sector -15.8% · RS bench -30% · 1Y -44.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.4 + 18.3 + 14 + 3.8 = 49.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Colgate-Palmolive (India) LtdCOLPAL | 47.5/100Mixed-negative evidence94% evidence | ASLEEP | 11.0/35 Revenue 3.8% · PAT -3.3% · OPM change -2 pp 100% evidence | 21.5/25 ROCE 108% · OPM 30% 100% evidence | 5.6/20 P/E 35.7× · PEG 6.07 100% evidence | 9.4/20 RS sector -1.5% · RS bench -12.9% · 1Y -25.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11 + 21.5 + 5.6 + 9.4 = 47.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 8Zydus Wellness LtdZYDUSWELL | 42.3/100Mixed-negative evidence100% evidence | TURNING | 11.2/35 Revenue 66.3% · PAT -42.5% · OPM change -1 pp 100% evidence | 6.5/25 ROCE 4.9% · OPM 17% 100% evidence | 6.1/20 P/E 79.3× · PEG 1.75 100% evidence | 18.5/20 RS sector 27.6% · RS bench 17% · 1Y 13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 6.5 + 6.1 + 18.5 = 42.3 · Decision use: Price leads the evidence: RS versus the benchmark is 17%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Emami LtdEMAMILTD | 37.7/100Mixed-negative evidence100% evidence | BASING | 7.7/35 Revenue 2.8% · PAT -8.2% · OPM change -1 pp 100% evidence | 14.3/25 ROCE 28.1% · OPM 22% 100% evidence | 9.3/20 P/E 21× · PEG 2.99 100% evidence | 6.4/20 RS sector -12.5% · RS bench -20.1% · 1Y -39.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.7 + 14.3 + 9.3 + 6.4 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jyothy Labs LtdJYOTHYLAB | 36.3/100Mixed-negative evidence100% evidence | BASING | 5.1/35 Revenue 3.9% · PAT -22.1% · OPM change -9 pp 100% evidence | 13.2/25 ROCE 28.7% · OPM 8% 100% evidence | 8.7/20 P/E 25.2× · PEG 5.24 100% evidence | 9.3/20 RS sector -12.2% · RS bench -19.9% · 1Y -41.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 5.1 + 13.2 + 8.7 + 9.3 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Godrej Consumer Products LtdGODREJCP | 31.7/100Adverse evidence100% evidence | ASLEEP | 15.6/35 Revenue 9.2% · PAT 3.3% · OPM change 0 pp 100% evidence | 9.6/25 ROCE 18.8% · OPM 19% 100% evidence | 3.4/20 P/E 42.6× · PEG 7.49 100% evidence | 3.1/20 RS sector -12.4% · RS bench -19.9% · 1Y -29.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 9.6 + 3.4 + 3.1 = 31.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Polo Queen Industrial and Fintech LtdPQIF | 34.3/100Thin evidence · provisional50% evidence | 15.1/35 Revenue -25.8% · PAT -16.1% · OPM change 0.3 pp 53% evidence | 7.7/25 ROCE 2.5% · OPM 7.6% 57% evidence | 8.5/20 P/E 223× · PEG — 15% evidence | 3.0/20 RS sector -54.8% · RS bench -58.4% · 1Y -61.4%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15.1 + 7.7 + 8.5 + 3 = 34.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Marico Ltd's share price today?
Marico Ltd trades at ₹802, +9.2% over the past year. The company is valued at ₹1,04,288 Cr. The stock sits at 57% of its 52-week range of ₹712–₹871, +0.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 73 weeks in. — as of 11 September 2026.
What were Marico Ltd's latest quarterly results?
Marico Ltd reported revenue of ₹3,957 Cr and net profit of ₹652 Cr for the Jun 26 quarter. Revenue rose 22.9% and profit rose 27.1% year on year. Earnings per share were ₹4.85. The operating margin was 21.0%, 1.0 pp higher than a year earlier. — as of 11 September 2026.
What is Marico Ltd's revenue?
Marico Ltd reported revenue of ₹3,957 Cr in the Jun 26 quarter, +22.9% year on year. For the full FY26 fiscal year, revenue was ₹13,611 Cr (+25.7%). Over the last 10 years revenue compounded at 8.5% a year. — as of 11 September 2026.
What is Marico Ltd's profit?
Marico Ltd earned ₹652 Cr of net profit in the Jun 26 quarter, +27.1% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹1,813 Cr. The operating margin ran 21.0% in the latest quarter. — as of 11 September 2026.
What is Marico Ltd's market cap?
Marico Ltd's market capitalisation is ₹1,04,288 Cr at a share price of ₹802. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Marico Ltd's P/E ratio?
Marico Ltd trades at a P/E of 55.2×, at the 74th percentile of its own 11-year range, against a long-run median of 51.8×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Marico Ltd pay a dividend?
Yes — Marico Ltd's dividend payout was 30% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Marico Ltd overvalued?
On its own history, Marico Ltd looks expensive: its P/E of 55.2× sits at the 74th percentile of its 11-year range (long-run median 51.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Marico Ltd growing?
Yes — Marico Ltd is growing: latest-quarter revenue +22.9% year on year, profit +27.1%, and the margin +1.0 pp at 21.0%. The 10-year compound rates are 8.5% (revenue) and 9.6% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Marico Ltd performing?
Marico Ltd is in a confirmed uptrend, 73 weeks in. Its latest quarter's revenue rose 22.9% and profit rose 27.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Marico Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 47.0% and holding. The read comes from the last 12 quarters of growth (revenue growth +25.1% latest, profit growth +15.0% latest, eps growth +12.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Marico Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 73 of stage 2), trading +0.5% versus its 200-day average and at 57% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Marico Ltd beating the market?
Not lately — on a trailing-13-week view Marico Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +238% against the NIFTY 500's +273% — behind the index over the full window. — as of 11 September 2026.
Will Marico Ltd's share price go up?
This page publishes no price forecast for Marico Ltd. What it measures instead: the share price is ₹802, the price is in a confirmed uptrend 73 weeks in. Its P/E of 55.2× sits at the 74th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Marico Ltd?
Promoters hold 58.9% of Marico Ltd, foreign institutions 23.4%, domestic institutions 12.9% and the public 4.5% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 1.8 points over 8 quarters. — as of 11 September 2026.
Does Marico Ltd have too much debt?
No — Marico Ltd's debt-to-equity is 0.13, and operating profit covers the interest bill 44×. FY26 borrowings were ₹557 Cr against equity of ₹4,210 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Marico Ltd's capex?
Marico Ltd spent ₹1,943 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,122 Cr, with ₹85.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Marico Ltd's cash flow?
Marico Ltd generated ₹2,084 Cr of operating cash flow in FY26 and ₹962 Cr of free cash flow after ₹1,122 Cr of capital spending. Reported profit that year was ₹1,813 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Marico Ltd's profit real cash?
Yes — over the last 3 fiscal years, 97% of Marico Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹2,084 Cr against reported profit of ₹1,813 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Marico Ltd in its business cycle?
Marico Ltd's FY26 operating margin was 17.0%, against a 13-year band of 15.0%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Marico Ltd story?
Biggest watch item: the P/E sits at the 74th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Marico Ltd a stock worth studying right now?
This is not investment advice. The machine read: Marico Ltd compounds quietly. Returns above 15% and growth without drama — priced like it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!